Abstract
INTRODUCTION
Non-small cell lung carcinoma (NSCLC) is one of the most malignant tumors and has the highest mortality rate in China. In addition to traditional treatments including surgery, radiotherapy, chemotherapy and mo-lecular targeted therapy, recently immunotherapy has gradually been gaining attention as a treatment option. 1 Dendritic cells (DCs), widely known for their role as antigen presenting cells (APCs), 2 also have anti-tumor functions achieved by regulating immune function. Previous studies have focused on the subcutaneous, venous and lymphatic administration of DCs. 3 However, thoracoscopy was shown to be the optimal method for administration. 4 Ginseng polysaccharides (GPS) have been shown to regulate the immune function of DCs in NSCLC patients. 5 However, no studies on the effect of GPS plus DCs administered thoracoscopically have been performed. Therefore, the present study was conducted in NSCLC patients examining the Functional Assessment of Cancer Treatment-Lung (FACT-L) scores, Th1 cytokines (INF-γ, IL-2) and the ratio of Th1/Th2 cytokines (INF-γ/IL-4,IL-2/IL-5) 6, 7 in BenQ hospital of Nanjing.
MATERIALS AND METHODS

Patients
A total of 96 patients diagnosed with NSCLC were recruited between January 2010 and July 2013 from BenQ hospital and randomly divided into two groups according to random number table: the control group and treatment group, with 48 patients per group. All patients were informed and the written informed consent forms were obtained. The study was approved by the ethics committee of BenQ hospital of Nanjing. The baseline characteristics between the two groups were not statistically significant (P>0.05, Table 1 ). 
Diagnostic criteria
Inclusion criteria
The inclusion criteria for the study were (a) meeting the diagnosis criteria for NSCLC, according to tumor staging international standards (TNM) for stage Ⅲ A and Ⅲ B, pathological classification for adenocarcinoma, nodular type; (b) having undergone first surgery and three to six cycles of chemotherapy regimens for NP, GP or EP; (c) cessation of chemotherapy for between 1 and 2 months prior to commencement of the study; (d) aged between 30 and 70 years old; (e) Karnofsky Performance Status (KPS) scores greater than 60 points; (f) signing informed consent form.
Exclusion criteria
The exclusion criteria for the study were (a) postoperative distant metastasis; (b) severe conditions of heart, cerebrovascular, liver, kidney or hematopoietic systems; (c) congenital disease or mental illness; (d) pregnancy or lactation.
Treatment
All cases were taken the foundation treatment such as postoperative symptomatic, supportive and targeted (erlotinib hydrochloride tablet, 150 mg/d, po.) remedy, there was no difference between the foundation treatment schemes adopted in each group (P>0.05). On the basis of the treatment, the control group was treated with DCs alone and the treatment group with GPS plus DC under the thoracoscope. Induction and self antigen load of DCs in peripheral blood: according to the reference, Table 1 Baseline clinical characteristics between patient groups (n=48, x ±s) Notes: control group was treated with DCs only; teatment group was treated with GPS plus DC. NP: vinorelbine and cisplatin; GP: gemcitabine and cisplatin; EP: etoposide and cisplatin; TNM: tumor staging international standards; GPS: ginseng polysaccharides; DC: dendritic cells. blood of patients with anticoagulant 100 ml, and collect 2 h-post wall composition of PBMNC (Peripheral Blood Mononuclear Cell) as precursor cells, With 2 × 10 6 /mL concentration to join serum-free medium AIM-V with gm-csf 1000 U/mL, IL-4 1000 U/mL. To cultivate at the environment of 37℃, 5%CO2, replace half quantity of culture liquid every 3 day. Cultured cells 5 days, add stimulus with tumor antigen 0.5 mL, At the same time to collect the patient's own tumor tissue in 5 days, join the TNF-α (tumor nectosis factor-alphagene) 20 ng/mL in the seventh day, DCs with tumor antigen was acquired in the eighth day. On this basis, To prepare for the next stage of treatment, the number, survival rate, sterile, gram staining, endotoxin, mycoplasma, purity and uniformity of cell quality of DCs were detected. Injection of DC or GPS add DC under the thoracoscope: the Storz type 260 thoracoscope (Karl Storz GmbH & Co., Tuttlingen, Germany) and the Stryker imaging system (Stryker, Kalamazoo, MI, USA) were used for thoracoscopic administration of DCs and GPS. DC cells number is 0.06×10 6 /kg, GPS is 0.5 mg/ kg, once a week, 4 times for 30 days. GPS injection was bought from Shanxi Pude pharmaceutical Co., Ltd., Shanxi, China; DCs was obtained from labolatory of Jiangsu shuyang hospital of TCM, Jiangsu, china. Indwelling 1 tube in chest drainage after the first injection, and arranged another injection with thoracoscope, strict control of infection, and strengthen the nursing of chest indwelling catheter for the prevention and treatment of pleural adhesion in the course of treatment,and given the extubation after treatment.
Data collection
Before and after treatment, the FACT-L scores were measured at dawn and 3 ml of venous blood collected in the morning, centrifuged force at 2220 × g for 10 min, and stored at -75℃ . After clotting, serum INF-γ, IL-4, IL-2, IL-5 levels were determined with double sandwich ELISA (enzyme-linked immuno sorbent assay) kits according to the manufacturer's instructions (Beijing Sizhengbai Biological Technology Co., Ltd., Beijing, China). ELISA plates were read on a Rainbow type spectrophotometer (Tecan Group Ltd., Mannedorf, Switzerland).
Statistical methods
Data are presented as the mean ± standard deviation (SD). The means of the two groups were compared using a t test. Statistical analysis was performed using SPSS version 19.0 (IBM Co., Ltd., Armonk, New York, USA).
RESULTS
FACT-L scores before and after treatment
The mean FACT-L score of each group decreased significantly after treatment (P<0.01). Furthermore, after treatment the mean FACT-L score in the control group was higher than that in the DC+GPS group (P< 0.05, Table 2 ). 5) were greater in the DC+GPS treatment group than in the control group, while conversely Th2 cytokines (IL-4, IL-5) were higher in the control group than in the DCs + GPS treatment group (P<0.05, Table 3 ).
Expression of Th1 and
DISCUSSION
Our study revealed that the FACT-L score in patients decreased after both interventions, and that the effect of GPS plus DCs was greater than that of DCs alone. This suggests that GPS interact with DCs to stimulate the immune system and that the secretion of cytokines is involved in the regulation of the immune response to NSCLC. Th1 and Th2 are the two major subtypes of CD4+ T lymphocytes. Th1 is linked to cell-mediated immunity and Th1 cells produce INF-γ and IL-2 and inhibit tumor cell proliferation. Th2 mediates the humoral immune can produce IL-4 , IL-5, and the other cytokines. In contrast to the Th1 response, the Th2 response can actually promote tumor cell prolifera- Table 2 FACT-L scores in the two patient groups before and after treatment (scores, n=48, x ±s) tion.
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Th1/Th2 cells are in a state of relative balance under normal circumstances. However, owing to abnormal immune function in patients with tumors, the dynamic balance of Th1/Th2 cytokines is altered, mainly with decreased function of Th1 and increased function of Th2 cells. 12 The DC has been the focus point of the field of biological tumor treatment in recent years. 13, 14 DC treatment aims to regulate the body's immune function by stimulating and enhancing specific anti-tumor immune response in patients with various forms of cancer. 15 Previous studies revealed that DCs regulated immune function in NSCLC patients through the balance of Th1/ Th2 cytokines. 16 Ginseng polysaccharides are antitumor agents isolated from Renshen (Radix Ginseng) that act through immune regulation. 17 Our findings demonstrate that Th1 and Th2 cytokines and the ratio of Th1/Th2 in the two groups were significantly changed after treatment. Specifically Th1 cytokines and the ratio of Th1/Th2 cytokines increased, while Th2 cytokines decreased. The effect evident in the GPS plus DCs group was greater than that of DCs alone. This may be evidence of synergism between GPS and DCs in regulating the immune function. Based on the above findings, the positive effect of GPS plus DCs on NSCLC patients' immune function was greater than that of using DC alone. This suggests that there is synergy between GPS and DCs when they were administered together. Table 3 Expression of Th1 and Th2 cytokines in the two patient groups before and after treatment (ng/L, n=48, x ±s)
